[
  {
    "ts": null,
    "headline": "FDA APPROVES UPLIZNA速 FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS",
    "summary": "Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA速 (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle specific tyrosine kinase (MuSK) antibody positive. The approval offers patients a new targeted treatment option that has the potential for long-term disease control with just two doses a year, after two initial loading doses.",
    "url": "https://finnhub.io/api/news?id=6cf537b9d006a926e39fb028c9c08ce2df4e4abd61538fdf1d224f8d799a674d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765494540,
      "headline": "FDA APPROVES UPLIZNA速 FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS",
      "id": 137767034,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA速 (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) and anti-muscle specific tyrosine kinase (MuSK) antibody positive. The approval offers patients a new targeted treatment option that has the potential for long-term disease control with just two doses a year, after two initial loading doses.",
      "url": "https://finnhub.io/api/news?id=6cf537b9d006a926e39fb028c9c08ce2df4e4abd61538fdf1d224f8d799a674d"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Insiders Sell US$15m Of Stock, Possibly Signalling Caution",
    "summary": "In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have...",
    "url": "https://finnhub.io/api/news?id=5a27d6520f139148d9fa0b8d42425e10380e247386675291f061cc6f0fa7ff83",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765458007,
      "headline": "Amgen Insiders Sell US$15m Of Stock, Possibly Signalling Caution",
      "id": 137757998,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "In the last year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a substantial stake in the company which may have...",
      "url": "https://finnhub.io/api/news?id=5a27d6520f139148d9fa0b8d42425e10380e247386675291f061cc6f0fa7ff83"
    }
  },
  {
    "ts": null,
    "headline": "Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly",
    "summary": "Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight loss medicines near market entry.",
    "url": "https://finnhub.io/api/news?id=f51c55eaad987bfbdde92a4861cd383e0f8cc9db88e505a213c9f2da47e6edcc",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765438786,
      "headline": "Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly",
      "id": 137759190,
      "image": "https://image.cnbcfm.com/api/v1/image/108198080-1757684463529-gettyimages-2177418373-20240909_cpupo_remedios_0832.jpeg?v=1757684482&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight loss medicines near market entry.",
      "url": "https://finnhub.io/api/news?id=f51c55eaad987bfbdde92a4861cd383e0f8cc9db88e505a213c9f2da47e6edcc"
    }
  }
]